Literature DB >> 32586651

VISTA deficiency protects from immune complex-mediated glomerulonephritis by inhibiting neutrophil activation.

El Li Tham1, Simon J Freeley1, Siobhan Bearder1, Fernanda Florez Barros1, Mark S Cragg2, Attila Mócsai3, Michael G Robson4.   

Abstract

V-type immunoglobulin domain-containing suppressor of T-cell activation (VISTA) is a negative checkpoint regulator of T cells. We assessed VISTA deficient mice in the murine nephrotoxic nephritis models of acute and chronic immune-complex mediated glomerulonephritis. We show that VISTA deficiency protects from crescentic glomerulonephritis, with no effect on the nephritogenic adaptive immune response. The early neutrophil influx was unaffected but proteinuria was reduced suggesting a reduction in neutrophil activation. In vivo, there was reduced neutrophil degranulation in VISTA deficienct mice and, in vitro, VISTA-deficient neutrophils had an impaired response to immune complexes but not to fMLP or PMA. Mice with a genetic deficiency of neutrophils due to myeloid-specific deletion of myeloid cell leukemia 1 (Mcl-1) were also protected from crescentic glomerulonephritis, indicating an essential role for neutrophils. Therefore, VISTA deficiency inhibits neutrophil activation by immune complexes and neutrophil-dependent crescentic glomerulonephritis. This suggests that VISTA is a therapeutic target for inflammatory disease. However, this would need to be balanced against a potential enhancing effect on autoimmunity.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Glomerulonephritis; Immune complex; Inflammation; Neutrophil

Year:  2020        PMID: 32586651     DOI: 10.1016/j.jaut.2020.102501

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  2 in total

1.  Distinct immune stimulatory effects of anti-human VISTA antibodies are determined by Fc-receptor interaction.

Authors:  Sven Mostböck; Helen Haixia Wu; Timothy Fenn; Bettina Riegler; Susanne Strahlhofer; Yining Huang; Gale Hansen; Rachel Kroe-Barrett; Iñigo Tirapu; Anne B Vogt
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

Review 2.  VISTA: A Promising Target for Cancer Immunotherapy?

Authors:  Marco Tagliamento; Elisa Agostinetto; Roberto Borea; Mariana Brandão; Francesca Poggio; Alfredo Addeo; Matteo Lambertini
Journal:  Immunotargets Ther       Date:  2021-06-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.